Add Formweb to your mobile device
9/17/21 cb INPATIENT Monoclonal Antibody Combinations Order Process
September 22, 2021
From: "Caitlin Bowman" <caitlin.bowman@hhsys.org>
To: "Pharmacists" <grp_allpharm@hhsys.org>
Sent: Friday, September 17, 2021 12:54:21 PM
Subject: INPATIENT Monoclonal Antibody Combinations Order Process
Monoclonal Antibody Combination Inpatient Order Process
Good afternoon pharmacists,
As a reminder, the monoclonal antibody combination products (bamlanivimab/etesevimab or casirivimab/imdevimab) can be used in special circumstances when the patient is hospitalized for something other than COVID-19 (i.e. heart attack, fall, etc.) but is incidentally found to be positive. This is in accordance with the FDA Emergency Use Authorization (EUA) and national guidelines (i.e. NIH, IDSA). Orders for monoclonal antibody combinations are strictly evaluated using the EUA criteria and HH Criteria for Use. The criteria for use for both of the monoclonal antibody combination products can be found under either the “COVID-19 for Pharmacy” page or on the “bamlanivimab-etesevimab” and “casirivimab-imdevimab” pages on FormWeb.
Currently, administration of the monoclonal antibody combination products occurs from 7am-3pm daily. Orders entered outside of this window will be evaluated on the next day and administered subsequently if the patient meets criteria. To help eliminate confusion, the Antimicrobial Management Team has created a flowchart (attached to this email & will be posted on FormWeb under the COVID-19 Info for Pharmacy tab) to help simplify the inpatient ordering process for the monoclonal antibody combinations.
Please follow the instructions included in the flowchart regarding new monoclonal antibody combination orders. Again, this is for inpatient administration (does not include Main ED or W&C ED).
As always, please contact AMT or the COVID-19 Hotline if you have any questions!